Nonalcoholic Fatty Liver Disease

Lingling Ding, Yvonne Oligschlaeger, Ronit Shiri-Sverdlov, Tom Houben

Research output: Chapter in Book/Report/Conference proceedingChapterAcademic


Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

Original languageEnglish
Title of host publicationPrevention and Treatment of Atherosclerosis
Subtitle of host publicationImproving State-of-the-Art Management and Search for Novel Targets
EditorsArnold von Eckardstein, Christoph J. Binder
Number of pages37
Publication statusPublished - 2022

Publication series

SeriesHandbook of Experimental Pharmacology


  • Humans
  • Metabolic Syndrome/epidemiology
  • Non-alcoholic Fatty Liver Disease/drug therapy

Cite this